immatics biotechnologies GmbH, a Tuebingen and Martinsried (Munich), Germany-based clinical-stage biopharmaceutical company, received €22m to complete a Series D financing round.
The company, which received €12m in October 2013 as an initial tranche of the total €34m funding round (read here), will use this funding to complete the current phase 3 trial with its lead cancer vaccine IMA901 in patients with renal cell carcinoma (RCC).
Backers include existing investors dievini Hopp Biotech holding, Wellington Partners, and AT Impf GmbH and others.
Led by Paul Higham, CEO, immatics develops advanced immunotherapies that are active against cancer. Its lead product, IMA901, is in a pivotal phase 3 study after completing a randomized phase 2 trial in renal cell carcinoma. The pipeline also includes IMA910, which has reported survival data in patients with advanced colorectal cancer, and IMA950, which has completed a phase 1 study in patients with glioma.
The company employs approx. 80 people.